Legal Representation
Attorney
Brett A. Manchel
USPTO Deadlines
Next Renewal Deadline
1898 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-09-17)
Due Date
September 17, 2030
Grace Period Ends
March 17, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
29 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 22, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Feb 27, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Feb 26, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Dec 20, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Sep 17, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Sep 17, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jul 8, 2024 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Jul 2, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jul 2, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 14, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jun 13, 2024 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Jun 12, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 29, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 29, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| May 29, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| May 29, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| May 29, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| May 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 9, 2024 | RFNT | P | REFUSAL PROCESSED BY IB |
| Apr 15, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Apr 15, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Mar 27, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Mar 26, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Mar 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 26, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Mar 22, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 21, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 001
Chemicals for use in industry and science; biological preparations for use in industry and science; chemical preparations for analytical and diagnostic purposes and laboratory use, namely, chemical preparations for analytical scientific purposes, chemical diagnostic reagents for scientific use, and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for use in protein analysis, other than for medical or veterinary purposes; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; chemicals and chemical products for biotechnological purposes, namely, chemicals for use in biotechnological product development; chemical products for immunoassay, namely, immunoassay reagents for non-medical purposes; antibody reagents for scientific purposes; antibodies for scientific purposes, other than for medical or veterinary use.
Class 005
Chemicals for medical purposes, namely, chemical reagents for medical purposes; chemicals for analytical purposes, namely, chemical reagents for medical use; biological preparations for use in cell cultures for medical purposes; antibodies for medical purposes; pharmaceuticals, namely, pharmaceutical preparations for treatment of autoimmune, inflammatory, cardiovascular, infectious, viral, cardiopulmonary, renal, gastrointestinal, respiratory, dermatological, oncological, heptalogical, neurological, musculoskeletal, bacterial, and metabolic diseases and disorders, and pharmaceutical preparations for treatment of cancer
Class 040
Custom manufacturing of antibodies for third parties; custom manufacture of pharmaceuticals
Class 042
Scientific research and development; pharmaceutical product development; consultancy pertaining to pharmacology; research and development services in the field of antibody technology
Additional Information
Design Mark
The mark consists of a design resembling a letter "Y" formed by seven circles.
Pseudo Mark
Y
Classification
International Classes
001
005
040
042